DaShenLin Pharmaceutical Group Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 11,700.7 million compared to CNY 9,436.9 million a year ago. Revenue was CNY 11,991.88 million compared to CNY 9,720.56 million a year ago.

Net income was CNY 917.43 million compared to CNY 714.19 million a year ago. Basic earnings per share from continuing operations was CNY 0.81 compared to CNY 0.625 a year ago. Diluted earnings per share from continuing operations was CNY 0.81 compared to CNY 0.625 a year ago.